DePuy Attune Knee Replacement

DePuy Attune Knee Replacement Lawsuit

DePuy Attune Knee Problems

The DePuy Synthes Attune total knee arthroplasty (TKA) system has been the subject of hundreds of complaints to the FDA about the knee device’s problems. The DePuy Attune Knee was introduced in 2010 and a recent study finds a higher than normal device failure rate. The failure seems to be related to the cement which holds the device in place.

Study of Attune Knee Replacement FDA Reports

The study,  published by the Journal of Knee Surgery, examined Manufacturer and User Facility Device Experience reports (MAUDEs) made to the FDA by manufacturers, hospitals,  doctors, patients, and consumers.  In particular, it studied patients who received a DePuy Attune TKA, and later required revision surgery. In looking at three hospitals, the study found 15 cases of tibial loosening of the cement on the implant.  Further, the study authors noted that there were 21 cases of tibial loosening reported to the FDA within the last two months alone. “Numerous other tibial failures” were reported without specifying how the failure occurred.

510(k) Fast Track Approval – Without Product Testing

The DePuy Attune knee system was fast-tracked by the FDA as DePuy represented to the FDA that the Attune knee system was “substantially similar” to  devices on the market. The 510(k) FDA approval process allows manufacturers to skip doing clinical trials on a product because it is so close to a product already on the market. DePuy submitted to the FDA that the Attune knee system was substantially equivalent to the following existing knee system devices:

  • PFC Sigma© Knee System (cleared as the Darwin Knee System), K943462
  • Sigma Patella (cleared s the Darwin Knee System), K950010
  • PFC Cruciate Retaining System, Size 1.5, K961685
  • Sigma Co-Cr Tibial Trays, K032151
  • Sigma XLK Tibial Inserts, K040166
  • Sigma CR 150 Femoral Components, K082500
  • Zimmer NexGen CR Knee System, K933785
  • AMK© Fixed Stem Tibial Tray, K922620

Attune Knee Problems

Despite DePuy’s claim  to the FDA that the Attune knee system was an improvement over existing knee replacement devices, Attune implant recipients began complaining about problems with their Attune knee systems. Problems reported by DePuy Attune knee implant recipients include:

  1.  Pain in the joint especially when weight bearing
  2.  Loosening of the joint
  3.  Heat or warmth in the knee
  4.  Joint instability
  5.  Grinding in the knee joint
  6.  Joint swelling
  7.  Water on the knee (effusion)
  8.  Dislocation of the device
  9.  Debonding of the device’s cement
  10.  Decreased range of motion (ROM)
  11.  Attune knee joint out of alignment
  12.  Nerve damage
  13.  Fracture of knee system components
  14.  Debris release from knee
  15.  Fracture of femur or tibia

FDA Attune Component Recall 2015

The Attune device was subject to a Class II FDA recall in 2015. The Attune  Knee Tibial Articulation Surface Instruments – tools used to implant the Attune knee implant – were recalled. One component of these, called a Balseal, contained a wire spring coil that could break off inside the patient without the doctor’s knowledge. That DePuy knee recall was terminated by the FDA on November 12, 2015.

Trust Our Massachusetts Attune Knee Implant Attorneys To Help

If you have experienced problems with an Attune knee replacement system, or with any other knee replacement, you may be eligible to file a personal injury claim for damages. You may be compensated for medical expenses from surgery to revise and replace your implant, and money damages for the pain, suffering, physical injuries, and any other losses, such as lost income,  that you suffered as a result of your injuries.

Call Attorney Marilyn McGoldrick at 1-888-341-1405  or contact the Boston law firm of Thornton Law Firm LLP online or for a confidential, no-cost consultation with a specialist in Massachusetts drug and medical device litigation. If you have had problems with an Attune knee implant,  you should seek legal advice as soon as possible, as courts apply strict time limits to all claims. Contact us today for a thorough, fair consideration of your legal claim.

Actemra (Tocilizumab)

What Is Actemra?

Actemra is prescribed for rheumatoid arthritis. It is a biologic drug, known as a monoclonal antibody. It is administered by injection every 1 to 2 weeks, or by intravenous infusion once a month. It is manufactured by Genentech, a subsidiary of Roche.

Why Is It Prescribed?

The FDA has approved Actemra as a medication for the following conditions:

  • Rheumatoid arthritis (moderate to severe)
  • Giant Cell Arteritis (GCA)
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA)
  • Systemic Juvenile Idiopathic Arthritis (SJIA)

How Does Actemra Work?

In rheumatoid artrhtis and other auto-immune diseases, the body’s own immune system begins to attack and destroy joints and tissue. Actemra works to suppress the immune system by blocking the protein interleukin-6, thereby preventing chronic inflammation.

Actemra, Heart Failure, and Pancreatitis

When Actemra was first approved, Genentech advertised the drug as “unique”, a breakthrough medication that didn’t carry a lot of the risks of other rheumatoid arthritis drugs. But a recent study published by STAT found over 1100 reports of deaths from heart or lung complications after using Actemra.

STAT analyzed more than 500,000 side-effect reports on rheumatoid arthritis drugs, and found clear evidence that the risks of heart attacks, strokes, heart failure, and other conditions were as high or higher for Actemra patients than for patients taking some competing drugs.

However, neither the manufacturer or the FDA has moved to inform patients of these serious health risks by adding them to the label of Actemra.

Actemra Side Effects and Injuries

The STAT investigators analyzed more then 500,000 side effect reports to the FDA and found that the risks of heart attacks, strokes, heart failure, and other conditions were higher for patients taking Actemra than for patients taking other rheumatoid arthritis drugs. Experts who examined the STAT data said the FDA should consider immediately adding warnings of the risk of heart failure and pancreatitis, an inflammation of the pancreas that has a high risk of death.

A 2016 study released by the  American College of Rheumatology in 2016 found that Actemra users had a 1.5 times greater risk of heart attack than patients taking Enbrel, a competing rheumatoid arthritis drug.

The FDA has also received reports of interstitial lung disease (lung scarring), strokes, gastrointestinal holes and tears, tachycardia (rapid heartbeat), tremors, and other side effects of Actemra.

What Can You Do?

If you or someone you love has taken Actemra and suffered heart failure and/or pancreatitis, you may have a legal claim for damages against the manufacturer. Call our Massachusetts Actemra lawyers toll free at 1-888-341-1405, or tell us your story using our online contact form.

Trust Our Massachusetts Actemra Lawyers to Help

Contact the Boston law firm of Thornton Law Firm LLP online or at 1-888-341-1405 for a free consultation with a recognized leader in Massachusetts drug and medical device litigation. You have nothing to risk. We offer a fair and accurate assessment of your case.

Talcum Powder and Ovarian Cancer

Ovarian cancer linked to talcum powder

Use of talcum powder on the genitals and perineal area, including on sanitary napkins, may raise a woman’s risk of developing ovarian cancer, according to scientific studies conducted since 1982. Millions of women have used Johnson & Johnson’s baby powder and Shower to Shower talc powders for years because J&J advertised them as safe for feminine hygiene use. Despite being aware of the studies linking talcum powder use and ovarian cancer, Johnson & Johnson has never placed warning labels on its talc powder products, even today. And they have failed to take the easy step of removing the talc powder from the market and selling the cornstarch powder they already produce.

What is talcum powder?

Talcum powder contains talc, a naturally-occurring, very soft mineral made up mainly of magnesium, silicon, and oxygen. Talcum powder has been sold for many years for use on babies and marketed to adults as a cosmetic and hygienic product.

How does talcum powder cause ovarian cancer?

Scientists are not sure exactly how talcum powder causes ovarian cancer. However, in many cases of ovarian cancer, talc is found in the ovarian tumor itself. Through its advertising, Johnson and Johnson advised that women sprinkle talcum powder in their genital area, and on underwear and sanitary pads. This was recommended to keep the vaginal area dry, to prevent chafing, and to cover up any odor of the vaginal area. Used in these areas, talcum powder can travel into the vagina, uterus, fallopian tubes and the ovaries.

Is it safe to use talcum powder?

Many pediatricians recommend against using talcum powder on babies. The American Pediatric Association recommends against using any powder on a baby, no matter the ingredients because inhaling powder can cause an inflammatory reaction in the lungs. The American Cancer Society advised in 1999 that women use cornstarch powder, rather than talcum powder, in the genital area.

Lawsuits against Johnson and Johnson and its talc suppliers

May, 2016:  A St. Louis jury awarded $72 million dollars to the family of a woman who developed ovarian cancer after using Johnson & Johnson’s talcum powder for many years. The jury awarded $10 million dollars in compensatory damages and $62 million dollars to the family of an Alabama woman. Plaintiff Jackie Fox died of ovarian cancer on October 6th. She had used Johnson & Johnson baby powder and “Shower to Shower” talcum powder for 35 years.

Fox’s family submitted expert medical testimony that talcum powder causes ovarian cancer. Statistical evidence presented at trial also showed that 1,500 women per year die from the association between talcum powder and ovarian cancer.

May, 2016: A South Dakota woman was awarded $55 million dollars against Johnson & Johnson for developing ovarian cancer after decades of using J&J talcum powder products. The jury awarded $5 million dollars in compensatory damages and $50 million dollars in punitive damages.

The plaintiff, Gloria Ristesund, was diagnosed with ovarian cancer in 2011 after using J&J Baby Powder and Shower to Shower powder as advertised, on her genital area, for almost 39 years. She is in remission after undergoing a full hysterectomy. Her lawsuit charged Johnson & Johnson of failing to warn of the cancer risk of using talcum powder or failing to remove talc from the powder and replace it with cornstarch which has similar soothing properties. The jury found in her favor after one day of deliberations following a three-week trial.

October, 2016:  A St. Louis jury awarded a California woman $70 million dollars in her lawsuit claiming that years of using Johnson & Johnson’s talc baby powder caused her ovarian cancer.

The 63-year-old plaintiff, Deborah Giannecchini, used Johnson & Johnson’s baby powder for feminine hygiene for four decades before she was diagnosed with Stage IV ovarian cancer in 2012. She has undergone multiple surgeries, radiation, and chemotherapy to treat cancer. Evidence was introduced that she has an 80% chance of dying in the next two years.

What can you do?

If you or a loved one has been diagnosed with ovarian cancer after using talcum powder, you may have a claim for damages. Contact the defective product lawyers at Thornton Law Firm for a free, confidential evaluation of your legal rights at 1-888-341-1405. Or tell us your story here for a free and thorough evaluation of your legal rights.

Trust our Massachusetts defective product attorneys to help

Contact Attorney Marilyn McGoldrick and tell her your story online or call her at 1-888-341-1405 for a free consultation with a recognized leader in Massachusetts defective product litigation. You have nothing to risk. We offer a fair and accurate assessment of your case.

Cipro, Levaquin, Avelox and Aortic Aneurysms

Aortic Side Effects From Fluoroquinolones

Widely prescribed antibiotics Cipro, Levaquin, and Avelox have been linked with aortic aneurysms and dissections, which are potentially fatal side effects. Fluoroquinolones are very strong antibiotics that are often prescribed for common infections like bronchitis, sinusitis, and urinary tract infections. Recent epidemiologic studies have shown significantly increased risk of serious aortic injuries in patients who have taken fluoroquinolone antibiotics. The FDA issued new warnings changing labeling of these drugs to reflect its advice “that fluoroquinolones should be reserved for these conditions only when there are no other options available due to potentially permanent, disabling side effects occurring together.”

What are Fluoroquinolones?

Fluoroquinolones are the most widely prescribed antibiotics in the United States. More than 26 million Americans are prescribed these antibiotics every year. The FDA Drug Safety Communication issued on May 12, 2016 (reemphasized in a second alert on July 26, 2016) strongly discourages the use of these antibiotics in uncomplicated infections. Finding the risks outweigh the benefits, the FDA recommended medical professionals avoid prescribing fluoroquinolones for sinusitis, bronchitis, urinary tract infections, and gynecological infections, unless there are no other treatment options.

The three most often prescribed fluoroquinolones are ciprofloxacin (Cipro, Cipro XR, Proquin XR); levofloxacin (Levaquin) and moxifloxacin (Avelox). Other drugs in this class are very infrequently prescribed: Factive (gemifloxacin), Floxin (ofloxacin) and Noroxin (norfloxacin).

What Are Aortic Dissection and Aneurysms?

The aorta is the main artery of the human body, beginning in the left ventricle of the heart and going down to the abdomen, where it branches into two smaller arteries. The aortic wall is tough, but studies link fluoroquinolones to damage to the lining of the aorta. An aortic dissection is a tear in the aortic wall. An aortic aneurysm is a weakness or a bulge where the aorta has become weak. Both conditions can lead to leaks, or rupture, which can be fatal.

Studies Link Fluoroquinolones and Aortic Aneurysms and Dissections

A study published in the Journal of the American Medical Association (JAMA) in 2013 found that use of fluoroquinolones was associated with a two-fold increased risk of developing aortic dissection or aneurysm within 60 days of exposure. The study authors advised: “[C]linicians should continue to be vigilant for the appearance of aortic aneurysm and dissection in high-risk patients treated with fluoroquinolones.” The British Medical Journal (BMJ) published a subsequent study which found that in over 650,000 patients taking fluoroquinolones, the risk of aortic aneurysms was almost tripled. That study concluded that reducing either fluoroquinolone prescriptions or prolonged courses of treatment might have prevented more than 200 aneurysms in the population studied.

What Can You Do?

If you or a loved one has been diagnosed with aortic dissection or aneurysm after taking a fluoroquinolone prescription, you may have a claim for damages. Contact the defective drug attorneys at Thornton Law Firm for a free, confidential evaluation of your legal rights at 1-888-341-1405. Or tell us your story using our online contact form.

Trust our Massachusetts Defective Drug Attorneys to Help

Contact the Attorney Marilyn McGoldrick online or at 1-888-341-1405 for a free consultation with a recognized leader in Massachusetts defective drug litigation. You have nothing to risk. We offer a fair and accurate assessment of your case.

Accutane

Generic name
• Isotretinoin

Date approved
• May 1982

Manufacturer
• Roche Laboratories Inc.

Status
• No longer available

Approved uses
• Treatment and prevention of severe acne

Serious side effects
• Birth defects
• Suicidal behavior
• IBD (inflammatory bowel disease)
• Crohn’s disease
• Death

What is Accutane?

Accutane (Isotretinoin) is a prescription drug manufactured by Roche laboratories and used to treat acne.

Who takes it, and for what condition?

Patients whose acne has not responded to other treatments take Accutane and its generic versions, Amnesteem, Claravis, and Sotret. Accutane is no longer sold, but the generics are still available.

How does Accutane work?

Accutane dries the oil produced by skin glands. Overproduction of the oil, known as sebum, leads to bacteria, which can cause acne.

Studies have linked problems such as inflammatory bowel disease (IBD), ulcerative colitis and Crohn’s disease to the use of Accutane. Other serious side effects include severe skin reactions.

What can you do?

If you have taken Accutane or one of its generic forms and believe you suffered from serious side effects such as birth defects, Crohn’s disease, or irritable bowel syndrome (IBS), you may have valuable legal rights. Please call our toll-free number (1-888-341-1405) to discuss your case with one of our Accutane injury lawyers.

Trust our Massachusetts Accutane injury attorneys to help

Contact the Boston law firm of Thornton Law Firm LLP online or at 1-888-341-1405 for a free consultation with a recognized leader in Massachusetts drug and medical device litigation. You have nothing to risk. We offer a fair and accurate assessment of your case, and, perhaps, some hope.

Actos

Generic name
• Pioglitazone hydrochloride

Date approved
• July 15, 1999

Manufacturer
• Takeda Pharmaceuticals, Inc. (Japan)

Co-marketer
• Eli Lilly and Company (U.S.A.)

Status
• On the market

Approved uses
• Type II diabetes

Serious side effects
• Increased bladder cancer risk
• Edema (accumulation of fluids)
• Swelling of the feet
• Congestive heart failure
•Hepatitis (swelling and inflammation of the liver)

What is Actos?

Actos (pioglitazone), manufactured by Takeda Pharmaceuticals, Inc. and co-marketed by Eli Lilly and Company, is in a class of diabetes drugs called thiazolidinediones or glitazones. Actos is manufactured in 3 strengths in tablet form: 15 mg, 30 mg, and 45 mg.

People with Type II diabetes take Actos to control blood sugar levels.

Actos is a glucose-lowering drug that increases the body’s sensitivity to insulin.

What side effects does Actos cause that weren’t on the original warning label?

  • Bladder cancer

In August of 2011, more than 11 years after Actos was first brought to market, the U.S. Food and Drug Administration (FDA) approved updated drug labels for Actos and other pioglitazone-containing medicines.  The new warnings informed patients that using pioglitazone for more than one year may be associated with an increased risk of bladder cancer.

The label update occurred after several studies showed an increased risk of bladder cancer with use of Actos. In June 2011, the FDA issued a Drug Safety Communication that warned that the use of this medication for more than one year has been associated with an increased bladder cancer risk. Six months later, the FDA approved updated labels for Actos to advise of the risk.

Medical regulators in France and Germany banned Actos in June 2011 because of the possibility of a bladder cancer risk. The decision was based on a French Medicines Agency study that found that people taking Actos were more likely to develop bladder cancer. The study examined cancer rates in about 155,000 people taking Actos in France from 2006 to 2009 and 1.3 million other diabetics who were not receiving the drug. The study found about a 22-percent higher risk of bladder cancer in diabetics taking the drug compared with those taking other drugs. The bladder cancer risk was highest in those receiving a cumulative dosage of at least 28,000 mg.

An earlier 2011 study examining more than 500,000 adverse event reports to the FDA between 2004-2009 suggested that Actos patients faced a “disproportionate risk” of bladder cancer. The study looked at reports associated with various diabetes medications and found that one-fifth of those involving bladder cancer occurred in patients using the drug.

  • Heart disease

In addition to bladder cancer, the American Heart Association and American Diabetes Association warned diabetics who have mild heart disease or kidney problems that they might be at risk for congestive heart failure if they take thiazolidinediones. The FDA required Actos to carry a boxed warning about congestive heart failure and other cardiac risks in 2007.

What can you do?

If you or someone you love took Actos and suffered from serious side effects, including bladder cancer, edema (accumulation of fluids), swelling of the feet, congestive heart failure, or hepatitis (swelling and inflammation of the liver), you have valuable legal rights. Please call our toll-free number (1-888-341-1405) to discuss your case with one of our Actos lawyers.

Trust our Massachusetts Actos injury attorneys to help

Tell Thornton Law Firm your story online or call 1-888-341-1405 for a free consultation with a recognized leader in Massachusetts drug and medical device litigation. You have nothing to risk. We offer a fair and accurate assessment of your case.

Avandia Quick Reference Guide

Avandia Quick Reference Guide

Generic name
• Rosiglitazone maleate

Date approved
• May 28, 1999

Manufacturer
• GlaxoSmithKline

Status
• On the market

Approved uses
• Type II diabetes

Serious side effects
• Edema (accumulation of fluids)
• Swelling of the feet
• Congestive heart failure
• Hepatitis

What is Avandia?

Avandia (rosiglitazone), manufactured by GlaxoSmithKline, is a top-selling drug for Type II diabetes.

Who takes it, and for what condition?

People with Type II diabetes take Avandia.

How does Avandia work?

Avandia helps control blood sugar levels by making diabetics more sensitive to their own insulin.

Studies have found that people who take Avandia have an increased risk for heart attacks and strokes.

On September 23, 2010 the U.S. Food and Drug Administration announced that it will restrict the use of Avandia to patients with Type II diabetes who cannot control their diabetes with other medications.

What can you do?

If you or a loved one took Avandia and suffered from serious side effects, including heart attack or fatal congestive heart failure, you have valuable legal rights. Please call our toll-free number ( 1-888-341-1405 ) to discuss your case with one of our Avandia injury lawyers.

Contact the Boston law firm of Thornton Law Firm LLP online or at 1-888-341-1405  for a free consultation with a recognized leader in Massachusetts drug and medical device litigation. You have nothing to risk. We offer a fair and accurate assessment of your case, and, perhaps, some hope.

Bair Hugger Warming Blankets and Infection

What Is a Bair Hugger?

Bair Hugger Warming Blankets, manufactured by 3M, are used to keep surgical patients warm. But studies have raised concerns about the potential to transmit infection as warm air circulates from the rest of the surgical room to the surgical site.

Contact the Boston law firm of Thornton Law Firm LLP online or at  1-888-341-1405  for a free consultation with a recognized leader in defective medical device litigation.

Why Use a Bair Hugger?

Under general anesthesia, a patient’s temperature drops rapidly, putting the patient at risk of hypothermia, a dangerously low body temperature. Maintaining the normal body temperature of 98.6 reduces bleeding and recovery time. The Bair Hugger and other warming devices prevent perioperative hypothermia, a condition that can lead to infections, pressure sores, greater need for blood transfusions, and longer hospital stays.

How Does the Bair Hugger Work?

The Bair Hugger is a forced-air warming system. A disposable blanket is draped over (and sometimes under) the patient and connected to a heater/blower by a flexible hose. Warmed air accumulates under the blanket and escapes at the head of or the foot of the patient. This creates an airflow which brings air from underneath the surgical table and the floor into contact with the patient’s open wound.

What Are the Risks of Using a Bair Hugger Warming Blanket?

Studies have found that use of Bair Hugger warming blankets and other forced-air warming systems has the potential to introduce significant levels of bacteria and other contaminants into the surgical site.** This may increase the risk of infections and of deep joint infections. Patients have required multiple additional surgeries and amputations as a result. Patients who underwent heart surgery and hip or knee replacement are most susceptible to injuries as the result of the use of Bair Hugger warming blankets during those surgeries.

The inventor of the Bair Hugger, Dr. Scott D. Augustine, has come out against the continuing use of the Bair Hugger and other forced-air warming systems. In 2010 he told the New York Times he wants hospitals to stop using them:

These days, Dr. Augustine asserts that his invention is a danger to surgical patients receiving implant devices like artificial heart valves and joints. The forced air, he says, can spread bacteria associated with hospital-acquired infections.

What Can You Do?

If you or someone you love has been diagnosed with a severe infection after undergoing hip or knee replacement or heart surgery using a 3M Bair Hugger warming blanket and would like legal advice, contact the experienced medical device attorneys at Thornton Law Firm. Call 1-888-341-1405  and ask to speak with Attorney Marilyn McGoldrick. Or tell us your story using our online form for a free, no-obligation consultation regarding your legal rights. Bair Hugger lawsuits have short, strictly enforced time limits, so seek legal advice as soon as possible.

  • A 2010 study in the American Journal of Infection Control concluded that forced-air warmers are ‘inadequate’ for ‘preventing the internal buildup and emission of microbial contaminants into the operating room.’
  • A 2011 study published in the Journal of Bone and Joint Surgery (British Volume) found a ‘significant increase in deep joint infection, as demonstrated by an elevated infection odds ratio’ and recommended air-free warming over forced-air warming for orthopaedic procedures.
  • A 2012 study published in the Journal of Bone and Joint Surgery (British Volume) found that forced-air warming increases the number of particles over the surgical site (as compared with radiant warming) and concluded that the study finding ‘raises concern as bacteria are known to require particles for transport.’
  • A 2012 study published in Anaesthesia compared a Bair Hugger to an over-body conductive blanket and an under-body resistive mattress, and concluded that the Bair Hugger ‘generates convection current activity in the vicinity of the surgical site’. The authors warn that those currents ‘may disrupt ventilation airflows intended to clear airborne contaminants from the surgical site’.
  • A 2013 study published in Anesthesia and Analgesia comparing a Bair Hugger to other warming devices found ‘forced air warming was found to establish convection currents that mobilized resident air from nonsterile areas (under the anesthesia drape) upward and into the surgical site’.

Contact the Boston law firm of Thornton Law Firm LLP online or at 1-888-491-9726 for a free consultation with a recognized leader in consumer litigation.  You have nothing to risk. We offer a fair and accurate assessment of your case.

Benicar (Olmesartan)

Daiichi_Sankyo_manufacturer_of_Benicar

WHAT IS BENICAR? WHY IS IT PRESCRIBED?

Benicar — generic name olmesartan medoxomil, referred to as olmesartan — is a blood pressure medication. It is used to lower blood pressure.

Made by Daiichi Sankyo, Benicar was approved by the FDA in 2002 for the treatment of high blood pressure.

Other drugs that contain Benicar include Benicar HCT, Azor (amlodipine and olmesartan), Tribenzor (amlodipine, hydrochlorothiazide and olmesartan) and generics.

HOW DOES BENICAR WORK?

Benicar belongs to the class of drugs called ARBS — Angiotensin Receptor Blockers. ARBS block the hormone angiotensin from constricting the blood vessels. Benicar causes the blood vessels to relax (dilate), allowing blood to flow more easily, thereby lowering blood pressure.

BENICAR AND SEVERE GASTROINTESTINAL SIDE EFFECTS

A study done at the Mayo Clinic in 2012 showed that taking Benicar increased the patient’s risk of an intestinal condition known as sprue-like enteropathy. Sprue-like enteropathy is characterized by severe, chronic diarrhea and substantial weight loss.

In July of 2013, the FDA ordered the manufacturers to add a warning to the label about the risk of enteropathy on Benicar, Benicar HCT, Azor, Tribenzor, and generics containing olmesartan.

WHAT CAN YOU DO?

If you or someone you love has taken Benicar or any other olmesartan-containing blood pressure medication and suffered severe gastrointestinal side effects, including chronic diarrhea and weight loss, you may have a legal claim for damages against the manufacturer. Call our Massachusetts Benicar lawyers toll free at 1-888-341-1405, or tell us your story using our online contact form.

TRUST OUR MASSACHUSETTS BENICAR LAWYERS TO HELP

Contact the Boston law firm of Thornton Law Firm LLP online or at 1-888-341-1405 for a free consultation with a recognized leader in Massachusetts drug and medical device litigation. You have nothing to risk. We offer a fair and accurate assessment of your case.

Byetta and Januvia

Quick Facts

Byetta and Januvia Reference Guide

Generic Name

  • sitagliptin phosphate

Date Approved

  • 10/17/2006

Manufacturer

  • Merck & Co., Inc.

Status

  • On the market

Approved Uses

  • Treatment of type 2 diabetes

Serious Side Effects

  • Pancreatitis
  • Renal impairment
  • Thyroid cancer
  • Pancreatic cancer

Linked to Pancreatitis, Pancreatic Cancer, and Thyroid Cancer

Our firm is investigating potential lawsuits on behalf of patients who suffered from pancreatitis, pancreatic cancer or thyroid cancer related to the use of glucagon-like peptide-1-based therapies such as Byetta (exenatide) and Januvia (sitagliptin).

These two medications are prescription medicines used to treat Type 2 diabetes, which occurs when there is not enough insulin to break down sugar in the body.

Byetta and Januvia are is a GLP-1 agonist, meaning that it tries to help increase the activity of the hormone. Glucagon-like peptide-1 (GLP-1) is a gut hormone that helps secrete insulin. Research has linked glucagon-like peptide -1-based therapies such as this to an increased risk of pancreatitis, pancreatic cancer and thyroid cancer.

In 2011, Gastroenterology journal published a study definitively linking pancreatitis, pancreatic cancer and thyroid cancer to GLP-1 based therapies. The study, conducted by researchers at the University of California, Los Angeles (UCLA) found a higher incidence of pancreatitis and pancreatic cancer associated with Byetta and Januvia compared with other therapies. Furthermore, researchers also found a significantly higher rate of thyroid cancer linked to the use of Byetta.

For a free evaluation of your case, please contact us by filing our online form, or by calling our toll-free number: 1-888-341-1405.

Byetta, Januvia and Pancreatitis

Pancreatitis is inflammation of the pancreas, the organ responsible for secreting digestive enzymes. It is also involved in regulating blood sugar because it releases the hormones insulin and glucagon. Pancreatitis occurs when the digestive enzymes become active while still inside the pancreas (instead of the small intestine). This condition, which can occur acutely or develop as chronic condition, can cause damage to the pancreas. Signs of acute pancreatitis include:

  • Upper abdominal pain that may radiate to the back
  • Swollen and tender abdomen
  • Nausea
  • Vomiting
  • Fever
  • Increased heart rate

According to the Gastroenterology study, pancreatitis was six times more common among patients who took Byetta compared to those who took an alternative type 2 diabetes therapy.

How we can help

Thornton Law Firm LLP has been a leader in investigating and pursuing compensation for consumers who have been injured by defective drugs and medical devices for more than 30 years. We have a team of attorneys dedicated to this complex area of law. We understand your rights, what is at stake, and how to handle drug claims from beginning to end. For a free evaluation of your case, please contact us by filing our online form, or by calling our toll-free number: 1-888-341-1405.

Links:

Contact Us